No Data
Hong Kong stocks rose 9% as Wuxi Bio (02269) industry recovery signal gradually appeared. The industry continued to grow driven by the warming up of innovative policies.
Wuxi Bio (02269) rose more than 9%, as of press time, rose 9.14%, reported at HKD 11.46, with a turnover of HKD 0.914 billion.
Trending Industry Today: WUXI XDC Leads Gains In Biotech and Pharmaceutical Stocks
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
Changes in the CRO concept stocks rose in the morning, with Wuxi Apptec's quarterly net income increasing compared to the previous quarter, and Pharmaron achieving a double-digit growth in newly signed order amounts.
On July 31st, CRO concept stocks rose in early trading. As of press time, Wuxi Bio (02269.HK) rose 8.19% to HK$11.36; Wuxi AppTec (02359.HK) rose 8.04% to HK$32.25; Tigermed (03347.HK) rose 7.59% to HK$29.75; Asymchem Laboratories (06821.HK) rose 5.98% to HK$47; Pharmaron (03759.HK) rose 5.97% to HK$9.59. Market information source: Futubull. On the news front, the evening of July 29th.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
China Securities Co., Ltd. expects that the "expanding domestic demand" trade will gradually grow, covering cyclical and growth stocks.
China Securities Co.,Ltd. released a research report stating that it is expected that the 'expanding domestic demand' trade will gradually grow, covering both cyclical and growth stocks.
No Data
